PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Size: px
Start display at page:

Download "PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland"

Transcription

1 AWARD NUMBER: W81XWH TITLE: Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? PRINCIPAL INVESTIGATOR: Gary Ulaner, MD, PhD CONTRACTING ORGANIZATION: Memrial Slan Kettering Cancer Center New Yrk, NY, REPORT DATE: Oct 2016 TYPE OF REPORT: Annual Reprt PREPARED FOR: U.S. Army Medical Research and Materiel Cmmand Frt Detrick, Maryland DISTRIBUTION STATEMENT: Apprved fr Public Release; Distributin Unlimited The views, pinins and/r findings cntained in this reprt are thse f the authr(s) and shuld nt be cnstrued as an fficial Department f the Army psitin, plicy r decisin unless s designated by ther dcumentatin.

2 REPORT DOCUMENTATION PAGE Frm Apprved OMB N Public reprting burden fr this cllectin f infrmatin is estimated t average 1 hur per respnse, including the time fr reviewing instructins, searching existing data surces, gathering and maintaining the data needed, and cmpleting and reviewing this cllectin f infrmatin. Send cmments regarding this burden estimate r any ther aspect f this cllectin f infrmatin, including suggestins fr reducing this burden t Department f Defense, Washingtn Headquarters Services, Directrate fr Infrmatin Operatins and Reprts ( ), 1215 Jeffersn Davis Highway, Suite 1204, Arlingtn, VA Respndents shuld be aware that ntwithstanding any ther prvisin f law, n persn shall be subject t any penalty fr failing t cmply with a cllectin f infrmatin if it des nt display a currently valid OMB cntrl number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED Octber 2016 Annual Reprt 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER 4 Culd HER2 Hetergeneity Open New Therapeutic Optins in Patients with HER2- Primary Breast Cancer? 30 Sep Sep b. GRANT NUMBER W81XWH c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Gary Ulaner ulanerg@mskcc.rg 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Memrial Slan Kettering Cancer Center 1275 Yrk Avenue New Yrk, NY, d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Cmmand Frt Detrick, Maryland SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Apprved fr Public Release; Distributin Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The purpse f this study is t determine if targeted imaging with a HER2-targeting PET tracer can detect HER2-psitive metastases in patients with HER2-negative primary breast cancer. Twenty-three patients have been accrued t the trial. Nine patients demnstrated suspicius fci n 89 Zr-trastuzumab PET/CT. Tw f nine patients with suspicius fci had bipsy-prven HER2-psitive metastases. Thus, 89 Zr-trastuzumab PET/CT may detect HER2-psitive metastases in patients with presumed HER2-negtive primary breast cancer. This is an initial prf-f-cncept that targeted imaging may help identify patients eligible fr targeted therapies. Hwever, false-psitive results limit the ability f 89 Zr-trastuzumab t be translated int clinical use, and a mre specific raditracer will be needed. 15. SUBJECT TERMS Breast cancer, HER2, tumr hetergeneity, PET/CT, 89 Zr-trastuzumab 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT Unclassified b. ABSTRACT Unclassified c. THIS PAGE Unclassified 18. NUMBER OF PAGES Unclassified 10 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area cde) Standard Frm 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

3 Table f Cntents Page 1. Intrductin Keywrds Accmplishments Impact Changes/Prblems Prducts Participants & Other Cllabrating Organizatins Special Reprting Requirements 7 9. Appendices Federal Financial Reprt

4 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? 1. INTRODUCTION: Human epidermal grwth factr receptr 2 (HER2) is a highly valuable bimarker in breast cancer, and its expressin directly influences treatment. Grwing evidence suggests that HER2 expressin may change between the primary breast malignancy and metastases. This is an example f tumr hetergeneity. Inaccurate knwledge f receptr status in metastases due t tumr hetergeneity may lead t subptimal treatment f metastatic breast cancer. Our central hypthesis is that imaging with a targeted HER2 raditracer will allw us t identify patients with HER2-negative primary breast cancers wh develp HER2-psitive metastases, and wh may benefit frm the additin f HER2 therapy. 2. KEYWORDS: Breast cancer Human epidermal grwth factr receptr 2 (HER2) Tumr hetergeneity PET/CT Targeted imaging 89 Zr-trastuzumab 3. ACCOMPLISHMENTS: What were the majr gals f the prject? Task 1. Submissin and apprval f regulatry dcuments 1a. IND fr 89 Zr-trastuzumab 1b. IRB Prtcl Task 2. Determine the prprtin f patients with HER2- primary breast cancer wh develp imagable HER2+ metastases using a targeted HER2 raditracer (Specific Aim #1) 2a. Accrue 50 patients at a rate f 1-2 per mnth 2b. Cnfirm HER2- status f archived pathlgy tissue samples 2c. 89 Zr-trastuzumab PET/CT t identify patients suspicius fr HER2+ metastases 2d. Bipsies t cnfirm HER2+ malignancy 2e. Interim statistical analyses as predefined accrual numbers are met Task 3. Amng patients with HER2+ metastases discvered in Specific Aim #1, determine if HER2-targeted therapy results in a measurable treatment respnse (Specific Aim #2) 3a. Pre-treatment baseline disease assessments with FDG PET and CT 3b. HER2-targeted systemic therapy 3c. Pst-treatment disease assessments with FDG PET and CT 3d. Final statistical analyses 1

5 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? What was accmplished under these gals? Task 1. Submissin and apprval f regulatry dcuments 1a. IND fr 89 Zr-trastuzumab IND fr 89 Zr was cmpleted and maintained 1b. IRB Prtcl IRB fr study prtcl was cmpleted and maintained. Task 2. Determine the prprtin f patients with HER2- primary breast cancer wh develp imagable HER2+ metastases using a targeted HER2 raditracer 2a. Accrue 50 patients at a rate f 1-2 per mnth 23 patients were accrued t the prtcl as f 30-Sep b. Cnfirm HER2- status f archived pathlgy tissue samples HER2- status f archived pathlgy samples was cnfirmed fr all patients. 2c. 89 Zr-trastuzumab PET/CT t identify patients suspicius fr HER2+ metastases 89 Zr-trastuzumab PET/CT was perfrmed in all patients. Nine patients had 89 Zrtrastuzumab fci suspicius fr HER2+ disease. 2d. Bipsies t cnfirm HER2+ malignancy Bipsies were perfrmed in all nine patients with 89 Zr-trastuzumab fci suspicius fr HER2+ disease. Tw f nine were psitive fr HER2+ disease n pathlgy (true psitives) Seven f nine were nt psitive fr HER2+ disease n pathlgy (false psitives) 2e. Interim statistical analyses as predefined accrual numbers are met Interim statistical analyses were perfrmed. Task 3. Amng patients with HER2+ metastases discvered in Specific Aim #1, determine if HER2-targeted therapy results in a measurable treatment respnse 3a. Pre-treatment baseline disease assessments with FDG PET and CT Pre-treatment baseline disease assessments were perfrmed in the tw patients with bipsy-prven, HER2+ metastases. 3b. HER2-targeted systemic therapy HER2-targeted systemic therapy was perfrmed in the tw patients with bipsy-prven, HER2+ metastases. 3c. Pst-treatment disease assessments with FDG PET and CT 2

6 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? Pst-treatment disease assessments were perfrmed in the tw patients with bipsyprven, HER2+ metastases. Bth patients demnstrated respnse t HER2-targeted therapy (ne cmplete, ne partial). 3d. Final statistical analyses Final statistical analyses are pending. What pprtunities fr training and prfessinal develpment has the prject prvided? Nthing t reprt Hw were the results disseminated t cmmunities f interest? The first manuscript fr this prject has been published: Detectin f HER2-psitive metastases in patients with HER2-negative primary breast cancer using the 89 Zr-DFO-trastuzumab PET/CT. Ulaner et al, Jurnal f Nuclear Medicine 2016, e-published ahead f print, PMID: The first presentatin fr the prject has been made: Detectin f HER2-psitive metastases in patients with HER2-negative primary breast cancer using 89 Zr-DFO-trastuzumab, Ulaner et al, Annual Meeting f the Sciety f Nuclear Medicine and Mlecular Imaging, San Dieg, Califrnia, June What d yu plan t d during the next reprting perid t accmplish the gals? The bjective f the study (detectin f HER2+ metastases in patients with presumed HER2- disease) has been accmplished. This is a prf-fcncept that targeted imaging may help identify patients eligible fr targeted therapies. Hwever, the high rate f false psitives limits the usefulness f 89 Zr-trastuzumab t be translated t the clinic. A mre specific raditracer will be needed. We have spken with ur DD Science fficer, Julia M. Huiberts, and have cme up with a plan t btain an Investigatinal New Drug (IND) applicatin frm the Fd and Drug Administratin (FDA) fr a ptentially mre specific HER2-targeting PET raditracer, 89 Zr-pertuzumab, and perfrm the remainder f this trial with 89 Zr-pertuzumab. This will delay the cmpletin f the study by the time it takes t btain the 89 Zr-pertuzumab IND frm the FDA (estimated t be ne year); hwever, this change may increase the specificity f ur HER2- targeted imaging.

7 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? 4. IMPACT: What was the impact n the develpment f the principal discipline(s) f the prject? The results already demnstrate the prf-f-cncept that targeted imaging can be used t help identify patients eligible fr targeted therapies. What was the impact n ther disciplines? The initial results cnfirm that there may be hetergeneity f HER2 expressin between the primary malignancy and distant metastases. This adds t the grwing knwledge f tumr hetergeneity. What was the impact n technlgy transfer? Nthing t reprt. What was the impact n sciety beynd science and technlgy? Nthing t reprt. 5. CHANGES/PROBLEMS: The detectin f 89 Zr-trastuzumab fci that represent HER2- (rather than HER2+) metastatic breast cancer is cnsidered a prblem. As previusly mentined, we have spken with ur DD Science fficer, Julia M. Huiberts, and have cme up with a plan t btain an IND applicatin frm the FDA fr a ptentially mre specific HER2-targeting PET raditracer, 89 Zr-pertuzumab, and perfrm the remainder f this trial with 89 Zrpertuzumab. This will delay the cmpletin f the study by the time it takes t btain the 89 Zr-pertuzumab IND frm the FDA (estimated t be ne year); hwever, this change may increase the specificity f ur HER2-targeted imaging. Changes in apprach and reasns fr change We will change frm 89 Zr-trastuzumab t 89 Zr-pertuzumab imaging, a ptentially mre specific antibdy cnjugate, t attempt t increase specificity f HER2-targeted imaging. Actual r anticipated prblems r delays and actins r plans t reslve them Use f 89 Zr-pertuzumab will require an IND applicatin t the FDA. This will delay the cmpletin f the study by the time it takes t btain the 89 Zr-pertuzumab IND frm the FDA (estimated t be ne year). Changes that had a significant impact n expenditures Nthing t reprt. Significant changes in use r care f human subjects, vertebrate animals, bihazards, and/r select agents Nthing t reprt. 4

8 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? Significant changes in use r care f human subjects Nthing t reprt. Significant changes in use r care f vertebrate animals. Nthing t reprt. Significant changes in use f bihazards and/r select agents Nthing t reprt. 6. PRODUCTS: Publicatins, cnference papers, and presentatins Jurnal publicatins. Ulaner et al, Jurnal f Nuclear Medicine 2016, e-published ahead f print, PMID: Bks r ther nn-peridical, ne-time publicatins. Nthing t reprt. Other publicatins, cnference papers, and presentatins. Detectin f HER2-psitive metastases in patients with HER2-negative primary breast cancer using 89 Zr-DFO-trastuzumab, Ulaner et al., Annual Meeting f the Sciety f Nuclear Medicine and Mlecular Imaging, San Dieg, Califrnia, June 2016 Website(s) r ther Internet site(s) Nthing t reprt. Technlgies r techniques Nthing t reprt. Inventins, patent applicatins, and/r licenses Nthing t reprt. Other Prducts Nthing t reprt. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS What individuals have wrked n the prject? Prvide the fllwing infrmatin fr: (1) PDs/PIs; and (2) each persn wh has wrked at least ne persn mnth per year n the prject during the reprting perid, regardless f the surce f cmpensatin (a persn mnth equals apprximately 160 hurs f effrt). If infrmatin is 5

9 Ulaner, Gary PROGRESS REPORT: Octber 2016 DD W81XWH Culd HER2 hetergeneity pen new therapeutic ptins in patients with HER2- primary breast cancer? unchanged frm a previus submissin, prvide the name nly and indicate "n change." Name: Gary Ulaner (PI): N change Name: Hanh Pham (Research Assistant): N change Has there been a change in the active ther supprt f the PD/PI(s) r senir/key persnnel since the last reprting perid? Nthing t reprt What ther rganizatins were invlved as partners? Nthing t reprt 7. SPECIAL REPORTING REQUIREMENTS COLLABORATIVE AWARDS: Nt applicable QUAD CHARTS: Nt applicable. 8. APPENDICES: Nne. ****************************************************************************** ********** ADDITIONAL NOTES: n/a 6

Kessler Foundation West Orange, NJ PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Kessler Foundation West Orange, NJ PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-16-1-0726 TITLE: A Randmized Cntrlled Trial f the Grup-Based Mdified Stry Memry Technique in TBI PRINCIPAL INVESTIGATOR: Nancy D. Chiaravallti, PhD CONTRACTING ORGANIZATION: Kessler

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W8XWH-5--0087 TITLE: Evaluating the Feasibility f RESCUE: An Adjunctive HAI-Based Interventin fr Veterans with PTSD PRINCIPAL INVESTIGATOR: Dr. Peter Tuerk CONTRACTING ORGANIZATION: Charlestn

More information

AWARD NUMBER: W81XWH TITLE: Defining New Treatment Approaches for KRAS-Mutant Lung Cancer. PRINCIPAL INVESTIGATOR: Eric Collisson

AWARD NUMBER: W81XWH TITLE: Defining New Treatment Approaches for KRAS-Mutant Lung Cancer. PRINCIPAL INVESTIGATOR: Eric Collisson AWARD NUMBER: W8XWH-3--0225 TITLE: Defining New Treatment Appraches fr KRAS-Mutant Lung Cancer PRINCIPAL INVESTIGATOR: Eric Cllissn CONTRACTING ORGANIZATION: University f Califrnia, San Francisc San Francisc,

More information

W81XWH TITLE: PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH

W81XWH TITLE: PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH AWARD NUMBER: 1310486 XXXXXX W81XWH-13-1-0486 TITLE: Recgnitin f Chrnic Traumatic Encephalpathy thrugh FDDNP PET Imaging PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH CONTRACTING ORGANIZATION: Cleveland

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0503 TITLE: Effect of Diabetes and Obesity on Disparities in Prostate Cancer Outcomes PRINCIPAL INVESTIGATOR: Bettina F. Drake, MPH, PhD CONTRACTING ORGANIZATION: Washington University

More information

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021 AD Award Number: DAMD17-94-J-4376 TITLE: Position Emitter I124 Iododeoxyuridine as a Tracer to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison of 18F 2-Fluror-2-Deoxy-(D)-Glucose,

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0503 TITLE: Effect of Diabetes and Obesity on Disparities in Prostate Cancer Outcomes PRINCIPAL INVESTIGATOR: Bettina F. Drake, MPH, PhD CONTRACTING ORGANIZATION: Washington University

More information

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD AWARD NUMBER: W81XWH-15-1-0520 TITLE: Gulf War Illness as a Brain Autoimmune Disorder PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD CONTRACTING ORGANIZATION: Regents University of Minnesota Minneapolis,

More information

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors

TITLE: Managing Menopausal Symptoms in Breast Cancer Survivors '.;* * AD GRANT NUMBER: DAMD17-94-J-4507 TITLE: Managing Menpausal Symptms in Breast Cancer Survivrs PRINCIPAL INVESTIGATOR: Patricia A. Ganz, M.D. CONTRACTING ORGANIZATION: University f Califrnia, Ls

More information

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D. AWARD NUMBER: W81XWH-16-1-0429 TITLE: Androgen Deprivation Therapy and Cognitive Impairment PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D. CONTRACTING ORGANIZATION: Western University of Health Sciences

More information

Award Number: W81XWH

Award Number: W81XWH Award Number: W81XWH-14-2-0193 TITLE: Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy PRINCIPAL INVESTIGATOR: Thomas

More information

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer AD Award Number: W81XWH-10-1-0824 TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer PRINCIPAL INVESTIGATOR: Joanne Mortimer, M.D. CONTRACTING ORGANIZATION: City of

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Distribution Unlimited

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Distribution Unlimited AWARD NUMBER: W81XWH-12-1-0236 TITLE: PRINCIPAL INVESTIGATOR: EF5 PET of Tumor Hypoxia: A Predictive Imaging Biomarker of Response to Stereotactic Ablative Radiotherapy (SABR) for Early Lung Cancer Billy

More information

Approved for public release; distribution unlimited

Approved for public release; distribution unlimited Award Number: W81XWH-16-1-0763 TITLE: Increasing Bone Mass and Bone Strength in Individuals with Chronic Spinal Cord Injury: Maximizing Response to Therapy PRINCIPAL INVESTIGATOR: Thomas J. Schnitzer,

More information

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720 AD Award Number: W81XWH-05-1-0526 TITLE: Effects of Extracellular Matix on DNA Repair in Vivo PRINCIPAL INVESTIGATOR: Aylin Rizki, Ph.D. CONTRACTING ORGANIZATION: University of California Lawrence Berkeley

More information

TITLE: Pathways to Disease: The Biological Consequences of Social Adversity on Asthma in Minority Youth

TITLE: Pathways to Disease: The Biological Consequences of Social Adversity on Asthma in Minority Youth AWARD NUMBER: W81XWH-15-1-0116 TITLE: Pathways t Disease: The Bilgical Cnsequences f Scial Adversity n Asthma in Minrity Yuth PRINCIPAL INVESTIGATOR: Neeta Thakur, MD CONTRACTING ORGANIZATION: University

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0479 TITLE: Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease PRINCIPAL INVESTIGATOR:

More information

Statement of Work for Linked Data Consulting Services

Statement of Work for Linked Data Consulting Services A. Backgrund Infrmatin Statement f Wrk fr Linked Data Cnsulting Services The Natinal Library f Medicine (NLM), in Bethesda, Maryland, is a part f the Natinal Institutes f Health, US Department f Health

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0546 TITLE: Assessing EphA2 and Ephrin-A as Novel Diagnostic and Prognostic Biomarkers of Prostate Cancer PRINCIPAL INVESTIGATOR: Carvell Tran Nguyen, MD PhD CONTRACTING ORGANIZATION:

More information

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation AWARD NUMBER: W81XWH-12-1-0559 TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation PRINCIPAL INVESTIGATOR: Jonathan R. Jagid, M.D. CONTRACTING ORGANIZATION:

More information

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes AD Award Number: DAMD17-01-1-0009 TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes PRINCIPAL INVESTIGATOR: Robert A. Vigersky CONTRACTING ORGANIZATION: Children s

More information

MGPR Training Courses Guide

MGPR Training Courses Guide MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,

More information

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism AWARD NUMBER: W81XWH-14-1-0293 TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism PRINCIPAL INVESTIGATOR: Armin Alaedini, PhD CONTRACTING ORGANIZATION: Trustees of Columbia

More information

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps. NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting

More information

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher: Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:

More information

Annual Assembly Abstract Review Process

Annual Assembly Abstract Review Process Annual Assembly Abstract Review Prcess AAHPM and HPNA cllabrate t review and select abstracts fr Annual Assembly. The cmmittees meet prir t the calls t review and update the Assembly bjectives (Planning

More information

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma AWARD NUMBER: W81XWH-14-1-0346 TITLE: Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma PRINCIPAL INVESTIGATOR: Lee, Menq-Jer,

More information

Appendix C. Master of Public Health. Practicum Guidelines

Appendix C. Master of Public Health. Practicum Guidelines Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum

More information

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors AWARD NUMBER: W81XWH-14-1-0073 TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors PRINCIPAL INVESTIGATOR: Kevin A. Roth, MD, PhD CONTRACTING

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer AD (Leave blank) Award Number: DAMD17-03-1-0575 TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer PRINCIPAL INVESTIGATOR: Judy Garber CONTRACTING ORGANIZATION: Dana-Farber

More information

TITLE: Demonstrating the Efficacy of Group Prolonged Exposure Treatment of PTSD in OEF/OIF/OND Male Veterans

TITLE: Demonstrating the Efficacy of Group Prolonged Exposure Treatment of PTSD in OEF/OIF/OND Male Veterans AWARD NUMBER: W81XWH-15-1-0005 TITLE: Demonstrating the Efficacy of Group Prolonged Exposure Treatment of PTSD in OEF/OIF/OND Male Veterans PRINCIPAL INVESTIGATOR: K. Janet C de Baca CONTRACTING ORGANIZATION:

More information

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109 AWARD NUMBER: W81XWH-13-1-0463 TITLE: The Ketogenic Diet and Potassium Channel Function PRINCIPAL INVESTIGATOR: Dr. Geoffrey Murphy CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor,

More information

Decreasing Skin Graft Contraction through Topical Wound Bed Preparation with Anti-Inflammatory Agents. Tacoma, WA 98402

Decreasing Skin Graft Contraction through Topical Wound Bed Preparation with Anti-Inflammatory Agents. Tacoma, WA 98402 AWARD NUMBER: W81XWH-14-2-0153 TITLE: Decreasing Skin Graft Contraction through Topical Wound Bed Preparation with Anti-Inflammatory Agents PRINCIPAL INVESTIGATOR: Rodney Chan, MD CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Award Number: W81XWH-10-1-0585 TITLE: A Gene Expressin Prfile f BRCAness That Predicts fr Respnsiveness t Platinum and PARP Inhibitrs PRINCIPAL INVESTIGATOR: Panagitis Knstantinpuls CONTRACTING ORGANIZATION:

More information

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention AD AWARD NUMBER: DAMD17-02-1-0662 TITLE: Dietary Genistein and Prostate Cancer Chemoprevention PRINCIPAL INVESTIGATOR: Coral A. Lamartiniere, Ph.D. CONTRACTING ORGANIZATION: The University of Alabama at

More information

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman Page 1 AWARD NUMBER: W81XWH-16-1-0288 TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence PRINCIPAL INVESTIGATOR: Gary Nieman CONTRACTING ORGANIZATION: Upstate Medical University

More information

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast AD AWARD NUMBER: DAMD17-02-1-0569 TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast PRINCIPAL INVESTIGATOR: Kristin A. Skinner, M.D. CONTRACTING

More information

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards

More information

Fort Detrick, Maryland

Fort Detrick, Maryland Award Number: W81XWH-15-1-0636 TITLE: Effect of Diet on Gulf War Illness: A Pilot Study PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D. M.P.H CONTRACTING ORGANIZATION: Western Institute for Biomedical Research

More information

HSC 106 Personal Health Plan for Learning Activities & Assessment linked to Michigan Teacher Preparation Standards

HSC 106 Personal Health Plan for Learning Activities & Assessment linked to Michigan Teacher Preparation Standards HSC 106 Persnal Health Plan fr Learning Activities & Assessment linked t Michigan Teacher Preparatin Standards Standard 1 Cmpetency 1.1 Understand basic health cntent as it relates t schl health educatin.

More information

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc) AD Award Number: W81XWH-14-1-0347 TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc) PRINCIPAL INVESTIGATOR: Maria F. Czyzyk-Krzeska CONTRACTING ORGANIZATION: University

More information

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske AD (Leave blank) Award Number: W81XWH-12-1-0578 TITLE: Targeting Autophagy for the Treatment of TSC and LAM PRINCIPAL INVESTIGATOR: Elizabeth Henske CONTRACTING ORGANIZATION: Brigham and Women s Hospital

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0486 TITLE: Early Recognition of Chronic Traumatic Encephalopathy Through FDDNP PET Imaging PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH CONTRACTING ORGANIZATION: Cleveland

More information

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states.

Novel methods and approaches for sensing, evaluating, modulating and regulating mood and emotional states. Nvel methds and appraches fr sensing, evaluating, mdulating and regulating md and emtinal states. 2018 Jy Academic Grant Call fr Prpsals Intrductin The Annual Jy grant initiative aims t prmte and cntribute

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0408 TITLE: Pathogenesis and Prediction of Future Rheumatoid Arthritis PRINCIPAL INVESTIGATOR: Kevin D. Deane, MD/PhD CONTRACTING ORGANIZATION: Regents of the University of Colorado

More information

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression AD AWARD NUMBER: DAMD17-01-1-0352 TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression PRINCIPAL INVESTIGATOR: Yangfu Jiang, M.D., Ph.D. CONTRACTING ORGANIZATION: Long Island Jewish Medical

More information

ACRIN 6666 Screening Breast US Follow-up Assessment Form

ACRIN 6666 Screening Breast US Follow-up Assessment Form Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

TITLE: Mechanisms of Radiosensitization by the Neurotensin Receptor Antagonist SR48692 in Prostate Cancer Models

TITLE: Mechanisms of Radiosensitization by the Neurotensin Receptor Antagonist SR48692 in Prostate Cancer Models AD Award Number: W81XWH-08-1-0114 TITLE: Mechanisms f Radisensitizatin by the Neurtensin Receptr Antagnist SR48692 in Prstate Cancer Mdels PRINCIPAL INVESTIGATOR: Jarslaw Dziegielewski, Ph.D. CONTRACTING

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

Corporate Governance Code for Funds: What Will it Mean?

Corporate Governance Code for Funds: What Will it Mean? Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,

More information

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202 AD Award Number: DAMD17-03-1-0082 TITLE: Prevalence and Outcomes of Restless Legs Syndrome among Veterans PRINCIPAL INVESTIGATOR: Claire C. Bourguet, Ph.D. CONTRACTING ORGANIZATION: North Eastern Ohio

More information

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited AWARD NUMBER: W81XWH-13-1-0408 TITLE: Pathogenesis and Prediction of Future Rheumatoid Arthritis PRINCIPAL INVESTIGATOR: Kevin D. Deane, MD/PhD CONTRACTING ORGANIZATION: University of Colorado Denver,

More information

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT AD Award Number: W81XWH-10-1-0593 TITLE: Probiotic (VSL#3) for Gulf War Illness PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D., M.P.H. CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt

More information

Signature Assignment. Course. ANTH 2346: General Anthropology. Assignment ID (to be assigned) Outcomes/Rubrics to be Assessed by the Assignment

Signature Assignment. Course. ANTH 2346: General Anthropology. Assignment ID (to be assigned) Outcomes/Rubrics to be Assessed by the Assignment Signature Assignment ANTH 2346: General Anthrplgy Outcmes/Rubrics t be Assessed by the Assignment Cmmunicatin Critical Thinking Empirical and Quantitative Reasning Scial Respnsibility Assignment Descriptin

More information

Catherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support

Catherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support Catherine Wrthingham Fellws f APTA Instructins fr Writing a Letter f Supprt Fllwing is infrmatin designed t assist persns asked t write a letter f supprt fr a nminee fr the American Physical Therapy Assciatin

More information

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant IAEA-CN-233 Internatinal Experts Meeting n Severe Accident Management in the Light f the Accident at the Fukushima Daiichi Nuclear Pwer Plant Organized in cnnectin with the implementatin f the IAEA Actin

More information

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis AD Award Number: W81XWH-1-1-75 TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis PRINCIPAL INVESTIGATOR: Dr. David Broide CONTRACTING ORGANIZATION: University of California, San Diego

More information

Catherine Worthingham Fellows of the APTA Instructions for Nominators

Catherine Worthingham Fellows of the APTA Instructions for Nominators Catherine Wrthingham Fellws f the APTA Instructins fr Nminatrs The fllwing infrmatin was prepared t aid nminatrs in making a nminatin fr the APTA membership categry f Catherine Wrthingham Fellw. Please

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-15-1-0154 TITLE: Efficacy of the Direct Instruction Language for Learning (DI-LL) Program to Promote Expressive and Receptive Language in Children with Autism Spectrum Disorder PRINCIPAL

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Award Number: W81XWH-10-1-0593 TITLE: Probiotic (VSL#3) for Gulf War Illness PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D. M.P.H. CONTRACTING ORGANIZATION: Western Institute for Biomedical Research Salt Lake

More information

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239 AWARD NUMBER: W81XWH-16-1-0300 TITLE: Metformin Therapy for Fanconis Anemia PRINCIPAL INVESTIGATOR: Markus Grompe CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239 REPORT DATE:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-06-1-0093 TITLE: An Epigenetic Link to Prostate Cancer PRINCIPAL INVESTIGATOR: Raphael F Margueron, Ph.D. CONTRACTING ORGANIZATION: University of Medicine and Dentistry of New Jersey

More information

TITLE: Evaluation of Biomarkers Predictive of Benefit From PD-1 Inhibitor MK-3475 in Patients with Non-Small Cell Lung Cancer and Brain Metastases

TITLE: Evaluation of Biomarkers Predictive of Benefit From PD-1 Inhibitor MK-3475 in Patients with Non-Small Cell Lung Cancer and Brain Metastases AWARD NUMBER: W81XWH-15-1-0203 TITLE: Evaluation of Biomarkers Predictive of Benefit From PD-1 Inhibitor MK-3475 in Patients with Non-Small Cell Lung Cancer and Brain Metastases PRINCIPAL INVESTIGATOR:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Award Number: W81XWH-14-1-0077 TITLE: A NOVEL THERAPEUTIC FOR THE TREATMENT AND PREVENTION OF HEARING LOSS FROM ACOUSTIC TRAUMA PRINCIPAL INVESTIGATOR: DR. STEVEN HENRY HEFENEIDER CONTRACTING ORGANIZATION:

More information

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules Award Number: W81XWH-15-1-0127 TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules PRINCIPAL INVESTIGATOR: Ayumu Taguchi CONTRACTING ORGANIZATION: University of Texas MD

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-15-2-0060 TITLE: Prazosin for Prophylaxis of Chronic Post-Traumatic Headaches in OEF/OIF/OND Service Members and Veterans with Mild TBI PRINCIPAL INVESTIGATOR: Murray Raskind, MD CONTRACTING

More information

CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP

CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP I. Intrductin CALVIN JOHNSON JR. FOUNDATION 2015 PANCREATIC CANCER RESEARCH SCHOLARSHIP The Calvin Jhnsn Jr. Fundatin, Inc. (CJJRF) is a nn-prfit 501(c)(3) rganizatin funded in 2008 by Calvin MEGATRON

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin

More information

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation Award Number: W81XWH-10-1-0959 TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation PRINCIPAL INVESTIGATOR: Andrea Behrman CONTRACTING

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY

More information

The Cannabis Act and Regulations

The Cannabis Act and Regulations The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics

More information

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public

More information

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059 AD Award Number: W81XWH-05-1-0366 TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men PRINCIPAL INVESTIGATOR: Teletia R. Taylor, Ph.D. CONTRACTING ORGANIZATION: Howard University

More information

Frequently Asked Questions: IS RT-Q-PCR Testing

Frequently Asked Questions: IS RT-Q-PCR Testing Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld

More information

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk AD Award Number: W81XWH-04-1-0465 TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk PRINCIPAL INVESTIGATOR: Carrie Snyder CONTRACTING ORGANIZATION: Creighton University Omaha,

More information

IMMIGRATION Canada. Temporary Resident Visa. Los Angeles and New York City Visa Office Instructions. Table of Contents IMM 5876 E ( )

IMMIGRATION Canada. Temporary Resident Visa. Los Angeles and New York City Visa Office Instructions. Table of Contents IMM 5876 E ( ) IMMIGRATION Canada Table f Cntents Dcument Checklist Temprary resident visa Temprary Resident Visa Ls Angeles and New Yrk City Visa Office Instructins This applicatin is made available free by Immigratin,

More information

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals. 27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0463 TITLE: The Ketogenic Diet and Potassium Channel Function PRINCIPAL INVESTIGATOR: Dr. Geoffrey Murphy CONTRACTING ORGANIZATION: University of Michigan Ann Arbor, MI 48109

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-11-1-0626 TITLE: Treatment of Fragile X Syndrome with a Neuroactive Steroid PRINCIPAL INVESTIGATOR: Randi Hagerman, M.D. CONTRACTING ORGANIZATION: University of California, Davis Sacramento,

More information

TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma

TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma AWARD NUMBER: W81XWH-15-1-0411 TITLE: Central Tolerance Blockade to Augment Checkpoint Immunotherapy in Melanoma PRINCIPAL INVESTIGATOR: Maureen Su CONTRACTING ORGANIZATION: The University of North Carolina

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth

More information

Session78-P.doc College Adjustment And Sense Of Belonging Of First-Year Students: A Comparison Of Learning Community And Traditional Students

Session78-P.doc College Adjustment And Sense Of Belonging Of First-Year Students: A Comparison Of Learning Community And Traditional Students Sessin78-P.dc Cllege Adjustment And Sense Of Belnging Of First-Year Students: A Cmparisn Of Learning Cmmunity And Traditinal Students Jennifer Ann Mrrw, Ph.D. Assistant Prfessr Old Dminin University Department

More information

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year

Health Screening Record: Entry Level Due: August 1st MWF 150 Entry Year Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic

More information

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness AWARD NUMBER: W81XWH-13-1-0477 TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness PRINCIPAL INVESTIGATOR: Cathryn Bock CONTRACTING ORGANIZATION: Wayne State University REPORT DATE:

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

INTERIM REPORT JANUARY SEPTEMBER 2017

INTERIM REPORT JANUARY SEPTEMBER 2017 INTERIM REPORT JANUARY SEPTEMBER 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN Octber 27, 2017 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap):

More information

REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE

REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE REPORT ON OPERATIONS 2017 TELEPHONE CONFERENCE NO ONE SHOULD HAVE TO DIE WAITING FOR A NEW ORGAN February 12, 2018 MAGNUS NILSSON, CEO CHRISTOFFER ROSENBLAD, CFO NASDAQ OMX Stckhlm (mid cap): XVIVO HIGHLIGHTS

More information

CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical College of Cornell University New York, NY 10065

CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical College of Cornell University New York, NY 10065 AWARD NUMBER: W81XWH-14-1-0263 TITLE: Early Detection of NSCLC Using Stromal Markers in Peripheral Blood PRINCIPAL INVESTIGATOR: Dingcheng Gao CONTRACTING ORGANIZATION: Joan & Sanford I. Weill Medical

More information

REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES

REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES A Registered Reprt is a frm f empirical article ffered at Nature Human Behaviur in which the methds and prpsed analyses are pre-registered and reviewed

More information

2017 CMS Web Interface

2017 CMS Web Interface CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...

More information

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health AD Award Number: W81XWH-12-1-0170 TITLE: Prospective Evaluation of Intraprostatic Inflammation and Focal Atrophy as a Predictor of Risk of High-Grade Prostate Cancer and Recurrence after Prostatectomy

More information

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited CONTRACT NUMBER: W81XWH-16-1-0303 TITLE: Expliting Inhibitry Siglecs t Cmbat Fd Allergies PARTNERING INVESTIGATOR: Matthew Macauley, Ph.D. CONTRACTING ORGANIZATION: The Scripps Research Institute La Jlla,

More information

Hospital Preparedness Checklist

Hospital Preparedness Checklist Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been

More information

World Confederation for Physical Therapy Congress , May Singapore

World Confederation for Physical Therapy Congress , May Singapore Wrld Cnfederatin fr Physical Therapy Cngress 2015 1-4, May Singapre Call fr applicatins fr Chair f the Internatinal Scientific Cmmittee The Executive Cmmittee f WCPT invites applicatins and suggestins

More information

Ancillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community.

Ancillary Symposia Request for Proposals Partner with the Endocrine Society to Educatte the Endocrine Community. Ancillary Sympsia Request fr Prpsals Partnerr with the Endcrine Sciety t Educate the Endcrine Cmmunity. Jin the Endcrine Sciety in Bstn fr the 98 th Annual Meeting & Exp frm April 1 4, 2016. ENDO 2016

More information

Detection of Prostate Cancer Progression by Serum DNA Integrity

Detection of Prostate Cancer Progression by Serum DNA Integrity AD Award Number: TITLE: Detection of Prostate Cancer Progression by Serum DNA Integrity PRINCIPAL INVESTIGATOR: Dave S.B. Hoon, Ph.D. CONTRACTING ORGANIZATION: John Wayne Cancer Institute Santa Monica,

More information

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans AD (Leave blank) Award Number: W81XWH-09-2-0106 TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans PRINCIPAL INVESTIGATOR: Sarah D. Miyahira,

More information